They are not the household names, but the medications they are researching and developing could be the lifeline patients are waiting for. Today we explore how drug price controls—now making their way through Congress—could have unintended consequences for the small biotechs that are the engine of…

While the world’s attention has been rightfully focused on the hope of a breakthrough that will eradicate COVID-19, the private biotech sector has racked up record-breaking investments during the first half of 2020. As much of the economy falls victim to the global threat, venture capital funding…

Since the earliest days of biotech, the UK and the USA have worked together to move science forward and build globally competitive companies.  James Watson (US) and Francis Crick (UK) worked together to solve the structure of the molecule that underpins the industry. The two technologies on which…

Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

Dr. Benjamin Cowen is the CEO of ImmunoMet, a clinical stage biotech company developing anti-tumor and immune-metabolism therapies. Holding both a PhD and an MBA, Cowen has worked across the spectrum of companies, including large pharma, mid-sized pharma and small venture-backed companies and his…

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in…

This year marked the first time BIO’s Start-Up Stadium was part of the BIO World Congress on Industrial Biotechnology and Agtech. The Shark Tank-style forum provided innovators across industrial biotech and agtech unparalleled access to key members of the investment community, venture philanthropy…

In a few short months BIO will be hosting the BIO Investor Forum (#BIF19) for the 17th time. The event’s long history is testament to the continued appetite for partnerships, collaborations and investment in the exciting world of early stage biotech companies on the cusp of medical breakthroughs…

Roy Zwahlen took a long shot when he requested a meeting with an investment firm at the 2017 BIO International Convention in San Diego. As Assistant Dean for Innovation and Strategy at the UNC Eshelman School of Pharmacy and the Eshelman Institute for Innovation, Zwahlen was in search of a…